{"links": [{"source": 0, "target": "t5561", "value": "None"}, {"source": "t5561", "target": "t5562", "value": "None"}, {"source": "t5562", "target": "t5563", "value": "None"}, {"source": "t5563", "target": "t5565", "value": "None"}, {"source": "t5563", "target": "t5564", "value": "None"}, {"source": "t5563", "target": "d170", "value": "None"}, {"source": "t5565", "target": "t5566", "value": "None"}, {"source": "t5566", "target": "t5567", "value": "None"}], "nodes": [{"category": "disease", "id": 0, "name": "Menopause", "x": "250", "y": "350", "fixed": "true", "draggable": "true", "value": {"name": "Menopause"}}, {"category": "treatment", "id": "t5561", "name": "woman with menopausal symptoms", "draggable": "true", "value": {"name": "woman with menopausal symptoms", "type": "treatment related", "time": "", "intention": "", "description": "title:woman with menopausal symptoms", "drug": {}}}, {"category": "treatment", "id": "t5562", "name": "individualised care", "draggable": "true", "value": {"name": "individualised care", "type": "treatment related", "time": "", "intention": "", "description": "title:individualised carehead:Individualised careAdopt an individualised approach at all stages of diagnosis, investigation and management of menopause. See what NICE says on patient experience.SourcesThe NICE guidance that was used to create this part of the interactive flowchart. NG23", "drug": {}}}, {"category": "treatment", "id": "t5563", "name": "information and advice", "draggable": "true", "value": {"name": "information and advice", "type": "treatment related", "time": "", "intention": "clonidine\nhas been used for the treatment of attention deficit hyperactivity disorder\u2020 (adhd).161 162 163 164\nhas been used for the treatment of severe dysmenorrhea\u2020.\nhas been used topically\u2020 to reduce iop in the treatment of open-angle\u2020 (chronic simple) and secondary glaucoma\u2020 and hemorrhagic glaucoma associated with hypertension\u2020.b\nusually used to therapeutic advantage in antihypertensive therapy; however, carefully adjust dosage\ninjections containing a preservative should not be used to dilute the epidural injection.151", "description": "title:information and advicehead:Information and advicesubhead:Menopausal womenGive information to menopausal women and their family members or carers (as appropriate) that includes: an explanation of the stages of menopause  common symptoms (see below) and diagnosis  lifestyle changes and interventions that could help general health and wellbeing benefits and risks of treatments for menopausal symptoms long-term health implications of menopause. Explain to women that as well as a change in their menstrual cycle they may experience a variety of symptoms associated with menopause, including: vasomotor symptoms (for example, hot flushes and sweats) musculoskeletal symptoms (for example, joint and muscle pain) effects on mood (for example, low mood) urogenital symptoms (for example, vaginal dryness) sexual difficulties (for example, low sexual desire).Give information to menopausal women and their family members or carers (as appropriate) about the following types of treatment for menopausal symptoms: hormonal, for example HRT non-hormonal, for example clonidine non-pharmaceutical, for example cognitive behavioural therapy.Give information on menopause in different ways to help encourage women to discuss their symptoms and needs.Give information about contraception to women who are in the perimenopausal and postmenopausal phase. See guidance from the Faculty of Sexual & Reproductive Healthcare on contraception for women aged over 40 years.Discuss with women the importance of keeping up to date with nationally recommended health screening.NICE has written information for the public explaining its guidance on menopause.subhead:Women likely to go through menopause because of medical or surgical treatmentOffer women who are likely to go through menopause as a result of medical or surgical treatment (including women with cancer, at high risk of hormone-sensitive cancer or having gynaecological surgery) support and: information about menopause and fertility before they have their treatment (see what NICE says on cryopreservation in fertility) referral to a healthcare professional with expertise in menopause.Quality standardsThe following quality statement is relevant to this part of the interactive flowchart.5Information for women having treatment likely to cause menopauseSourcesThe NICE guidance that was used to create this part of the interactive flowchart. NG23", "drug": {"clonidine": "DB00964"}}}, {"category": "treatment", "id": "t5565", "name": "diagnosing perimenopause and menopause", "draggable": "true", "value": {"name": "diagnosing perimenopause and menopause", "type": "treatment related", "time": "", "intention": "", "description": "title:diagnosing perimenopause and menopausehead:Diagnosing perimenopause and menopauseDiagnose the following without laboratory tests in otherwise healthy women aged over 45 years with menopausal symptoms: perimenopause based on vasomotor symptoms and irregular periods menopause in women who have not had a period for at least 12 months and are not using hormonal contraception menopause based on symptoms in women without a uterus.Take into account that it can be difficult to diagnose menopause in women who are taking hormonal treatments, for example for the treatment of heavy periods.Do not use the following laboratory and imaging tests to diagnose perimenopause or menopause in women aged over 45 years: anti-M\u00fcllerian hormone inhibin A inhibin B\t oestradiol antral follicle count ovarian volume.Do not use a serum follicle-stimulating hormone test to diagnose menopause in women using combined oestrogen and progestogen contraception or high-dose progestogen.Consider using a follicle-stimulating hormone test to diagnose menopause only: in women aged 40 to 45 years with menopausal symptoms, including a change in their menstrual cycle in women aged under 40 years in whom menopause is suspected (see also diagnosing and managing premature ovarian insufficiency.Quality standardsThe following quality statement is relevant to this part of the interactive flowchart.1Diagnosing perimenopause and menopauseSourcesThe NICE guidance that was used to create this part of the interactive flowchart. NG23", "drug": {}}}, {"category": "treatment", "id": "t5564", "name": "premature ovarian insufficiency", "draggable": "true", "value": {"name": "premature ovarian insufficiency", "type": "treatment related", "time": "", "intention": "", "description": "title:premature ovarian insufficiencyhead:Diagnosing and managing premature ovarian insufficiencysubhead:DiagnosisTake into account the woman s clinical history (for example, previous medical or surgical treatment) and family history when diagnosing premature ovarian insufficiency.Diagnose premature ovarian insufficiency in women aged under 40 years based on: menopausal symptoms, including no or infrequent periods (taking into account whether the woman has a uterus) and elevated follicle-stimulating hormone levels on 2 blood samples taken 4\u20136 weeks apart.Do not diagnose premature ovarian insufficiency on the basis of a single blood test.Do not routinely use anti-M\u00fcllerian hormone testing to diagnose premature ovarian insufficiency.If there is doubt about the diagnosis of premature ovarian insufficiency, refer the woman to a specialist with expertise in menopause or reproductive medicine. subhead:ManagementOffer sex steroid replacement with a choice of HRT or a combined hormonal contraceptive to women with premature ovarian insufficiency, unless contraindicated (for example, in women with hormone-sensitive cancer).Explain to women with premature ovarian insufficiency: the importance of starting hormonal treatment either with HRT or a combined hormonal contraceptive and continuing treatment until at least the age of natural menopause (unless contraindicated) that the baseline population risk of diseases such as breast cancer and cardiovascular disease increases with age and is very low in women aged under 40 that HRT may have a beneficial effect on blood pressure when compared with a combined oral contraceptive that both HRT and combined oral contraceptives offer bone protection  that HRT is not a contraceptive.Give women with premature ovarian insufficiency and contraindications to hormonal treatments advice, including on bone and cardiovascular health, and symptom management. For more information, see what NICE says on osteoporosis and cardiovascular disease prevention.Consider referring women with premature ovarian insufficiency to healthcare professionals who have the relevant experience to help them manage all aspects of physical and psychosocial health related to their condition.Quality standardsThe following quality statements are relevant to this part of the interactive flowchart.2Diagnosing premature ovarian insufficiency3Managing premature ovarian insufficiencySourcesThe NICE guidance that was used to create this part of the interactive flowchart. NG23", "drug": {}}}, {"category": "treatment", "id": "t5566", "name": "managing menopausal symptoms", "draggable": "true", "value": {"name": "managing menopausal symptoms", "type": "treatment related", "time": "", "intention": "", "description": "title:managing menopausal symptoms", "drug": {}}}, {"category": "treatment", "id": "t5567", "name": "review and referral", "draggable": "true", "value": {"name": "review and referral", "type": "treatment related", "time": "", "intention": "", "description": "title:review and referralhead:Review and referralReview each treatment for short-term menopausal symptoms: at 3 months to assess efficacy and tolerability annually thereafter unless there are clinical indications for an earlier review (such as treatment ineffectiveness, side effects or adverse events).Refer women to a healthcare professional with expertise in menopause if treatments do not improve their menopausal symptoms or they have ongoing troublesome side effects.Consider referring women to a healthcare professional with expertise in menopause if: they have menopausal symptoms and contraindications to HRT or there is uncertainty about the most suitable treatment options for their menopausal symptoms.Quality standardsThe following quality statement is relevant to this part of the interactive flowchart.4Reviewing treatments for menopausal symptomsSourcesThe NICE guidance that was used to create this part of the interactive flowchart. NG23", "drug": {}}}, {"category": "drug", "id": "d170", "name": "clonidine", "draggable": "true", "value": {"name": "clonidine", "time": "None", "period": "None", "dosage": "None"}}]}